- Home
- UPXI vs AEON Comparison
UPXI vs AEON Comparison
Compare UPXI & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- AEON
- Stock Information
- Founded
- UPXI 2018
- AEON N/A
- Country
- UPXI United States
- AEON United States
- Employees
- UPXI N/A
- AEON N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- AEON Health Care
- Exchange
- UPXI Nasdaq
- AEON Nasdaq
- Market Cap
- UPXI 3.6M
- AEON 4.2M
- IPO Year
- UPXI 2021
- AEON N/A
- Fundamental
- Price
- UPXI $15.51
- AEON $0.43
- Analyst Decision
- UPXI
- AEON Strong Buy
- Analyst Count
- UPXI 0
- AEON 1
- Target Price
- UPXI N/A
- AEON $360.00
- AVG Volume (30 Days)
- UPXI 6.5M
- AEON 454.0K
- Earning Date
- UPXI 05-07-2025
- AEON 05-13-2025
- Dividend Yield
- UPXI N/A
- AEON N/A
- EPS Growth
- UPXI N/A
- AEON N/A
- EPS
- UPXI N/A
- AEON 72.93
- Revenue
- UPXI $18,625,089.00
- AEON N/A
- Revenue This Year
- UPXI $299.03
- AEON N/A
- Revenue Next Year
- UPXI N/A
- AEON N/A
- P/E Ratio
- UPXI N/A
- AEON $0.01
- Revenue Growth
- UPXI 4.75
- AEON N/A
- 52 Week Low
- UPXI $1.90
- AEON $0.38
- 52 Week High
- UPXI $22.53
- AEON $402.48
- Technical
- Relative Strength Index (RSI)
- UPXI 88.68
- AEON 26.24
- Support Level
- UPXI $9.81
- AEON $0.38
- Resistance Level
- UPXI $22.00
- AEON $0.48
- Average True Range (ATR)
- UPXI 2.41
- AEON 0.04
- MACD
- UPXI 1.41
- AEON 0.19
- Stochastic Oscillator
- UPXI 65.96
- AEON 52.76
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.